A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Trial Profile

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Acronyms INVICTUS
  • Sponsors Vaccitech
  • Most Recent Events

    • 19 Jan 2018 According to a Vaccitech media release, first round of participants has been recruited with over 862 people, this marks the end of the first phase of the trial, which will open again for new participants at the start of the winter flu vaccination programme in late 2018.
    • 15 Jan 2018 According to Vaccitech media release, till now 862 patients are enrolled in this study.
    • 31 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top